Gilead Sciences, Inc. $GILD Shares Sold by Mackenzie Financial Corp

Key Points

• Mackenzie Financial Corp cut its Gilead stake by 18% in Q3, selling 451,525 shares and now holding 2,063,924 shares (about 0.17% of the company) valued at roughly $229.1 million.
• Gilead agreed to acquire Arcellx for up to $7.8 billion to expand its oncology/cell‑therapy pipeline, and Jefferies initiated coverage with a Buy and $180 target, boosting institutional sentiment.
• Gilead raised its quarterly dividend to $0.82 (annualized $3.28, ~2.2% yield) and recently beat quarterly EPS estimates while setting FY2026 guidance of $8.45–$8.85 per share.

Mackenzie Financial Corp cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 18.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,063,924 shares of the biopharmaceutical company's stock after selling 451,525 shares during the period. Mackenzie Financial Corp owned 0.17% of Gilead Sciences worth $229,096,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of GILD. Brighton Jones LLC increased its position in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Bison Wealth LLC acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $215,000. Sivia Capital Partners LLC lifted its holdings in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company's stock worth $464,000 after purchasing an additional 602 shares during the last quarter. Vestmark Advisory Solutions Inc. bought a new position in Gilead Sciences in the 2nd quarter worth about $214,000. Finally, Penserra Capital Management LLC raised its holdings in Gilead Sciences by 1,241.2% during the second quarter. Penserra Capital Management LLC now owns 1,368 shares of the biopharmaceutical company's stock worth $151,000 after purchasing an additional 1,266 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Jefferies initiated coverage on Gilead with a Buy and $180 price target (≈21% upside vs. recent levels), which can attract fresh demand and lift sentiment among institutional investors. Jefferies coverage
• Positive Sentiment: Short interest fell ~15.7% in February to ~18.45M shares (1.5% of float), lowering potential short-squeeze dynamics and reducing downward pressure from bearish positioning; days-to-cover sits near 2.7 days based on average volume. (Data reported 3/10/2026)
• Positive Sentiment: Gilead agreed to acquire Arcellx (ACLX) for up to $7.8B — a deal meant to broaden Gilead’s cancer/ cell therapy pipeline; the acquisition signals management’s push into higher-growth oncology assets and helps explain investor buying. Gilead to acquire Arcellx
• Positive Sentiment: Market research (DelveInsight) forecasts strong expansion in the CD19 inhibitors market (oncology & autoimmune indications), supporting a favorable long-term backdrop for companies building CAR-T/ cell‑therapy franchises like Gilead. CD19 market outlook
• Neutral Sentiment: Gilead presented at the Leerink Global Healthcare Conference — the transcript may offer management color on pipeline timing, margins and M&A rationale but typically affects stock movement only after materially new guidance or data. Leerink presentation transcript
• Neutral Sentiment: Market write-ups (Yahoo/Zacks/247WallSt) noted Gilead’s outperformance and recent analyst coverage changes; these summaries reflect current momentum but are second‑order drivers unless paired with new data or ratings revisions. Market coverage

Gilead Sciences Stock Performance

NASDAQ GILD opened at $148.56 on Wednesday. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29. The company has a market capitalization of $184.43 billion, a P/E ratio of 21.94, a P/E/G ratio of 1.92 and a beta of 0.37. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The firm has a 50-day moving average price of $139.23 and a two-hundred day moving average price of $126.30.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts' consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion during the quarter, compared to analysts' expectations of $7.68 billion. During the same quarter in the prior year, the business earned $1.90 earnings per share. The business's revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a dividend of $0.82 per share. This is a boost from Gilead Sciences's previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences's dividend payout ratio (DPR) is 46.68%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on GILD. UBS Group lifted their price target on Gilead Sciences from $145.00 to $155.00 and gave the company a "buy" rating in a report on Monday, January 26th. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Citigroup restated a "buy" rating on shares of Gilead Sciences in a research report on Friday. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $150.00 to $160.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 11th. Finally, BMO Capital Markets increased their price target on shares of Gilead Sciences from $135.00 to $150.00 and gave the company an "outperform" rating in a research report on Monday, January 26th. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $157.62.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total value of $463,290.00. Following the transaction, the chief financial officer owned 167,779 shares in the company, valued at $25,910,110.97. The trade was a 1.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director directly owned 8,920 shares of the company's stock, valued at approximately $1,101,620. This represents a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 309,280 shares of company stock worth $43,935,470. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.